Logo image of CNTA

CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CNTA - US1523091007 - ADR

25.68 USD
+0.42 (+1.66%)
Last: 12/24/2025, 8:22:09 PM
25.65 USD
-0.03 (-0.12%)
After Hours: 12/24/2025, 8:22:09 PM
Fundamental Rating

2

Overall CNTA gets a fundamental rating of 2 out of 10. We evaluated CNTA against 530 industry peers in the Biotechnology industry. The financial health of CNTA is average, but there are quite some concerns on its profitability. CNTA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CNTA had negative earnings in the past year.
In the past year CNTA has reported a negative cash flow from operations.
In the past 5 years CNTA always reported negative net income.
In the past 5 years CNTA always reported negative operating cash flow.
CNTA Yearly Net Income VS EBIT VS OCF VS FCFCNTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

CNTA's Return On Assets of -54.14% is in line compared to the rest of the industry. CNTA outperforms 46.23% of its industry peers.
CNTA has a Return On Equity (-80.48%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -54.14%
ROE -80.48%
ROIC N/A
ROA(3y)-43.83%
ROA(5y)-56.62%
ROE(3y)-62.33%
ROE(5y)-121.67%
ROIC(3y)N/A
ROIC(5y)N/A
CNTA Yearly ROA, ROE, ROICCNTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

CNTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTA Yearly Profit, Operating, Gross MarginsCNTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

6

2. Health

2.1 Basic Checks

CNTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CNTA has more shares outstanding
The number of shares outstanding for CNTA has been increased compared to 5 years ago.
CNTA has a better debt/assets ratio than last year.
CNTA Yearly Shares OutstandingCNTA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M
CNTA Yearly Total Debt VS Total AssetsCNTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 11.05 indicates that CNTA is not in any danger for bankruptcy at the moment.
CNTA has a better Altman-Z score (11.05) than 83.02% of its industry peers.
A Debt/Equity ratio of 0.36 indicates that CNTA is not too dependend on debt financing.
CNTA's Debt to Equity ratio of 0.36 is on the low side compared to the rest of the industry. CNTA is outperformed by 70.94% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Altman-Z 11.05
ROIC/WACCN/A
WACC9.36%
CNTA Yearly LT Debt VS Equity VS FCFCNTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 10.57 indicates that CNTA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 10.57, CNTA belongs to the top of the industry, outperforming 83.40% of the companies in the same industry.
A Quick Ratio of 10.57 indicates that CNTA has no problem at all paying its short term obligations.
CNTA has a Quick ratio of 10.57. This is amongst the best in the industry. CNTA outperforms 83.40% of its industry peers.
Industry RankSector Rank
Current Ratio 10.57
Quick Ratio 10.57
CNTA Yearly Current Assets VS Current LiabilitesCNTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

2

3. Growth

3.1 Past

CNTA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.61%.
Looking at the last year, CNTA shows a very strong growth in Revenue. The Revenue has grown by 118.88%.
EPS 1Y (TTM)-2.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.81%
Revenue 1Y (TTM)118.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CNTA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.33% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.41%
EPS Next 2Y1.66%
EPS Next 3Y-1.36%
EPS Next 5Y16.33%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNTA Yearly Revenue VS EstimatesCNTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 2028 2029 2030 2031 2032 500M 1B 1.5B
CNTA Yearly EPS VS EstimatesCNTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNTA. In the last year negative earnings were reported.
Also next year CNTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTA Price Earnings VS Forward Price EarningsCNTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTA Per share dataCNTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.66%
EPS Next 3Y-1.36%

More info and screens

0

5. Dividend

5.1 Amount

CNTA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CENTESSA PHARMACEUTICALS-ADR

NASDAQ:CNTA (12/24/2025, 8:22:09 PM)

After market: 25.65 -0.03 (-0.12%)

25.68

+0.42 (+1.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-23 2026-03-23/amc
Inst Owners79.34%
Inst Owner Change3.96%
Ins Owners0.44%
Ins Owner Change-0.28%
Market Cap3.75B
Revenue(TTM)15.00M
Net Income(TTM)-242.70M
Analysts85.71
Price Target39.54 (53.97%)
Short Float %4.55%
Short Ratio3.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.73%
Min EPS beat(2)-7.99%
Max EPS beat(2)-3.48%
EPS beat(4)1
Avg EPS beat(4)2.12%
Min EPS beat(4)-27.41%
Max EPS beat(4)47.36%
EPS beat(8)4
Avg EPS beat(8)6.78%
EPS beat(12)7
Avg EPS beat(12)9.07%
EPS beat(16)9
Avg EPS beat(16)5.94%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)16.67%
PT rev (3m)18.03%
EPS NQ rev (1m)0.3%
EPS NQ rev (3m)5.92%
EPS NY rev (1m)-1.3%
EPS NY rev (3m)-0.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-4.54%
Revenue NY rev (3m)5.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 250.08
P/FCF N/A
P/OCF N/A
P/B 12.44
P/tB 12.44
EV/EBITDA N/A
EPS(TTM)-1.57
EYN/A
EPS(NY)-1.67
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0.1
BVpS2.06
TBVpS2.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -54.14%
ROE -80.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.83%
ROA(5y)-56.62%
ROE(3y)-62.33%
ROE(5y)-121.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.91%
Cap/Sales 2.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.57
Quick Ratio 10.57
Altman-Z 11.05
F-Score3
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)300.47%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.81%
EPS Next Y18.41%
EPS Next 2Y1.66%
EPS Next 3Y-1.36%
EPS Next 5Y16.33%
Revenue 1Y (TTM)118.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.2%
EBIT Next 3Y-20.31%
EBIT Next 5YN/A
FCF growth 1Y0.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.11%
OCF growth 3YN/A
OCF growth 5YN/A

CENTESSA PHARMACEUTICALS-ADR / CNTA FAQ

Can you provide the ChartMill fundamental rating for CENTESSA PHARMACEUTICALS-ADR?

ChartMill assigns a fundamental rating of 2 / 10 to CNTA.


Can you provide the valuation status for CENTESSA PHARMACEUTICALS-ADR?

ChartMill assigns a valuation rating of 0 / 10 to CENTESSA PHARMACEUTICALS-ADR (CNTA). This can be considered as Overvalued.


Can you provide the profitability details for CENTESSA PHARMACEUTICALS-ADR?

CENTESSA PHARMACEUTICALS-ADR (CNTA) has a profitability rating of 1 / 10.


What is the expected EPS growth for CENTESSA PHARMACEUTICALS-ADR (CNTA) stock?

The Earnings per Share (EPS) of CENTESSA PHARMACEUTICALS-ADR (CNTA) is expected to grow by 18.41% in the next year.